Nasdaq:US$16.32 (+0.02) | HKEX:HK$26.70 (+0.85) | AIM:£2.45 (-0.03)
Search Result

Your Search for:%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BDTalk:PC53%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%20%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%20%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%20%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD


THE LANCET Respiratory Medicine: Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Baogang Liu, Pinhua Pan, Dongqing Lv, Lin Wu, Yanqiu Zhao, Juan Li, Zhihua Liu, […]


HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 9, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer (“WCLC24”) in San Diego, USA, and the European Society for Medical […]


Corporate Presentation for Investors

Download latest HUTCHMED corporate presentation


Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at August 30, 2024, the issued share capital of HUTCHMED consisted of 871,469,720 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no […]


HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

Hong Kong, Shanghai & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma and will evaluate a new […]


Immune Thrombocytopenia Physician Expert Call

Date: Wednesday, August 28, 2024 Time: 7pm HKT


TR-1: Standard form for notification of major holdings

 TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: HUTCHMED (China) Limited 1b. […]


HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, August 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (“ITP”), to discuss the treatment landscape of ITP via webcast on Wednesday, August 28, 2024, at 7:00 […]


HUTCHMED Reports 2024 Interim Results and Provides Business Updates

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments.   HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. […]


2024 Half-Year Financial Results

  Announcement release:   July 31, 2024 (Wed) 7am EDT / 12 noon BST / 7pm HKT  >> View announcement here << Presentation webcast & call ➤  English Session: July 31, 2024 (Wed) 8am EDT / 1pm BST / 8pm HKT Watch Webcast Replay (English Session) ➤  Chinese (Putonghua) Session: Aug 1, 2024 (Thu) 8:30am HKT […]


Mr. Davy Yaojun HU

Mr Hu is the Director and President of Shanghai Hutchison Pharmaceuticals, HUTCHMED’s non-consolidated joint venture with Shanghai Pharmaceuticals. Mr Hu has over 20 years’ experience in management roles in pharmaceutical sales, marketing and medical affairs. Prior to joining the Company in 2016, Mr Hu worked in leading pharmaceutical companies including Merck, Sharp & Dohme and […]


Mr. George Yuan

Mr George Yuan is the Executive Vice President, Head of Commercial (China) of HUTCHMED. He leads and executes commercial strategy to meet the business strategy and needs of HUTCHMED. Prior to joining HUTCHMED, Mr. Yuan was Global VP, China Oncology Business Unit Head at Merck China (part of Merck KGaA, Germany) and a member of the global […]


Senior Manager, Financial Planning & Analysis

Job Title: Senior Manager, Financial Planning & Analysis Location: Hong Kong/Shanghai   Key Responsibilities Collaborate with the local finance team to prepare and review annual budgets, forecasts, monthly bookings, and long-range strategic plans; Monitor financial performance by measuring and analyzing results. Conduct analytical reviews on management reports to explain business performance; Provide operational support to […]


Associate Director/Director, Translational Research

Job Title: Associate Director/Director, Translational Research Location: Hong Kong   The individual is expected to play a leadership role for oncology and translational research in Hong Kong R&D.  He/She will lead the team to develop assays and platforms for evaluation of oncology drug candidates and exploring new biomarkers and indications of oncology drugs. In this […]


Senior technician for Oncology Research

Job Title: Senior technician for Oncology Research Location: Hong Kong   Key Responsibilities Daily operation and maintenance of laboratory instruments and equipment Order and storage of experiment expendable, reagents and materials Cell bank maintenance, including cell thawing, culturing, freezing procedures and documents Perform or support a variety of biology experiments Ensure strict adherence to relevant […]


Scientist/Senior Scientist for Oncology Research

Job Title: Scientist/Senior Scientist for Oncology Research Location: Hong Kong   Key Responsibilities Design and perform molecular and cell biology experiments, analyze data and draft study report Summary and presentation of study findings at internal or external meetings Research of tumor biomarkers, mechanism of action of new anti-cancer products and exploration of new indications or […]


Senior/Marketing Executive

Job Title: Senior/Marketing Executive Location: Hong Kong   Tasks and Responsibilities Provide support in branding operations & key marketing initiatives; Assist in defining, monitoring and achieving key performance metrics to inform strategy and support execution; Work closely with internal & external parties to ensure excellent execution in aligning marketing strategies with overall business goals; Create […]


HUTCHMED R&D Updates

➤  Chinese (Putonghua) Session: July 9, 2024 (Tue) 3pm HKT / 8am BST / 3am EST Listen to webcast replay (Chinese Session) ➤  English Session: July 9, 2024 (Tue) 8:30pm HKT / 1:30pm BST / 8:30am EST Listen to webcast replay (English Session)  


HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 4, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) has been accepted for review and granted Priority Review by the China National […]


Overseas regulatory announcements: Filing of Form F-3

Hong Kong, Shanghai & Florham Park, NJ: Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today filed the Form F-3 Registration Statement with the U.S. Securities and Exchange Commission.  This filing follows the expiration of the previous Form F-3 Registration Statement filed in 2020. The Form F-3 is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3865U_1-2024-6-28.pdf and also on […]


Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:   1. Name of applicant:   HUTCHMED (China) Limited   2. Name of scheme:   Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 […]


Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at June 28, 2024, the issued share capital of HUTCHMED consisted of 871,359,720 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no […]


HUTCHMED to Announce 2024 Half-Year Financial Results

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm […]


Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —   Hong Kong, Shanghai & Florham Park, NJ —  Monday, June 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024.   During the event, the senior […]


HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade —   Hong Kong, Shanghai & Florham Park, NJ — Friday, June […]


THE LANCET Haematology: Efficacy and safety of sovleplenib in adult patients with chronic primary ITP in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study Yu Hu*, Xiaofan Liu*, Hu Zhou*, Shujie Wang, Ruibin Huang, Yi Wang, Xin Du, Jing Sun, Zeping Zhou, Zhenyu Yan, Wenming Chen, Wei Wang, Qingchi Liu, Qingshu Zeng, Yuping Gong, Jie […]


HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA[1] exposure — — Data supported regulatory submission in China accepted in January 2024 —   Hong Kong, Shanghai & Florham Park, NJ — Monday, June 17, […]


HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

Hong Kong, Shanghai & Florham Park, NJ — Friday, June 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31, 2024. This is a Phase […]


Nature Medicine : Fruquintinib plus paclitaxel for gastric/ gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial Feng Wang, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yueyin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, […]


HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024   Hong Kong, Shanghai & Florham Park, NJ — Monday, June 3, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that results from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment […]


Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ — Friday, May 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at May 31, 2024, the issued share capital of HUTCHMED consisted of 871,264,820 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no […]


HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 […]


Goldman Sachs 45th Annual Global Healthcare Conference, Miami

Date: Monday, June 10, 2024 Time: 9:20am ET (1:20pm GMT / 9:20pm HKT) Listen to the Webcast  


HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

Hong Kong, Shanghai & Florham Park, NJ  — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and the appointment of Dr Dan Eldar as the new Chairman.   […]


HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM‑01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at […]


Dr. Renu Bhatia

Dr Renu Bhatia has been an Independent Non-executive Director of the Company since 2024. She is also a member of the Audit Committee and Technical Committee of the Company. A licensed physician, she has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors.   Dr Bhatia is the chairman and […]


HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui’s camrelizumab, promoting the immune response against tumor cells —   Hong Kong, Shanghai & Florham Park, NJ —  Tuesday, May 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; […]


HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, May 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their […]


Annual General Meeting held on May 10, 2024 – Poll Results

Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 10, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting (“AGM”) held on May 10, 2024 were duly passed.  The poll results of the resolutions were as follows: […]


HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees

Hong Kong, Shanghai & Florham Park, NJ  — Wednesday, May 8, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Dr Bhatia, a licensed physician, has […]


Cancer Immunology, Immunotherapy: Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer

Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer   Panpan Zhang, Zhendong Chen, Si Shi, Zhiping Li, Feng Ye, Lijie Song, Yanqiao Zhang, Fei Yin, Xing Zhang, Jianming Xu, Ying Cheng, Weiguo Su, Michael Shi, Songhua Fan, Panfeng […]


Jefferies Global Healthcare Conference, New York

Date: Wednesday, June 5, 2024 Time: 5:30pm ET (9:30pm GMT / 5:30am HKT on June 6) Listen to the Webcast  


BofA Securities Healthcare Conference 2024, Las Vegas

Date: Wednesday, May 15, 2024 Time: 2:20pm PDT (9:20pm GMT / 5:20am HKT on May 16) Listen to the Webcast  


HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO‑2 Phase III clinical trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, April 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) […]


Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Monday, April 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to the following persons discharging managerial responsibilities were vested on April 20, 2024:- Award Holder   Number of […]


ACS Medicinal Chemistry Letters: Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers

Hong Jia, Wei Deng, Baoyu Hao, Min Cai, Dong Guo, Yu Cai, Xiaoming Dai, Zhipeng Wu, Weigang He, Jian Wang, Guanglin Wang, Sumei Xia, Na Li, Weiguo Su, and Guangxiu Dai*       Abstract Herein we describe the medicinal chemistry efforts that led to the discovery of the clinical-staged Syk inhibitor sovleplenib (41) via […]


Sustainability

We are committed to embedding sustainability into all aspects of our operations, creating long-term value for our investors and stakeholders. Building on the substantial initiatives of the previous years and with reference to the latest sustainability standards, we developed a holistic sustainability framework covering areas that are central to our industry – climate action, innovation, […]


Sustainability Reports

View 2023 Report 1. ABOUT THIS REPORT 3 2. 2023 SUSTAINABILITY HIGHLIGHTS 4 3. MESSAGE FROM OUR CHAIRMAN 7 4. ABOUT HUTCHMED 9 5. SUSTAINABILITY GOVERNANCE 15 Sustainability Governance Structure 16 Risk Management 19 Sustainability & Governance Policies 21 6. SUSTAINABILITY STRATEGY 22 Stakeholder Engagement Approach 22 Developing a Holistic Sustainability Strategy 27 7. BUSINESS […]


Annual General Meeting 2024

Date: Friday, May 10, 2024 Time: 5:00 pm Hong Kong Time (10:00 am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong  


2023 Annual Report and Notice of Annual General Meeting

Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 8, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2023 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”), will be posted on April 9, 2024 to those shareholders who have elected […]


HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Hong Kong, Shanghai & Florham Park, NJ — Friday, April 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in […]


HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor —   Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent […]


HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and expand indication to more patients —   Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 28, 2024: HUTCHMED (China) […]


Dissemination of Corporate Communications

PRINCIPAL SHARE REGISTRAR Computershare Investor Services (Jersey) Limited 13 Castle Street, St. Helier Jersey, Channel Islands JE1 1ES Telephone: +44 (0)370 707 4040 Facsimile: +44 (0)370 873 5851 HONG KONG BRANCH SHARE REGISTRAR Computershare Hong Kong Investor Services Limited Shops 1712-1716, 17th Floor Hopewell Centre, 183 Queen’s Road East Wanchai, Hong Kong Telephone: +852 2862 […]


HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Hong Kong, Shanghai & Florham Park, NJ — Friday, March 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China.   This follows positive data from the proof-of-concept […]


Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, March 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options (“Share Options”) under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share Option Scheme”) and awards (“LTIP Awards”) under the Long Term Incentive Plan […]


Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2023 annual results of HUTCHMED on February 28, 2024, the following awards granted under the Long Term Incentive Plan (“LTIP”) on March 26, 2021 to Dr Weiguo Su and […]


HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation   Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 28, 2024: HUTCHMED […]


2023 Full Year Financial Results

Announcement release: Feb 28, 2024 (Wed) 6:30am EST / 11:30am GMT / 7:30pm HKT  >> View announcement here << Presentation webcast & call ⯈ English Session: Feb 28, 2024 (Wed) 7:30am EST / 12:30pm GMT / 8:30pm HKT Listen to the webcast replay (English Session) ⯈ Chinese (Putonghua) Session: Feb 29, 2024 (Thu) 7:30pm EST […]


HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (“ASCO”) Plenary […]


HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

Hong Kong, Shanghai & Florham Park, NJ — Friday February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the “Options”) pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the […]


HUTCHMED to Announce 2023 Final Results

Hong Kong, Shanghai & Florham Park, NJ — Thursday, February 1, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong […]


HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in […]


European Journal of Cancer: Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial   Panpan Zhang, Si Shi, Jianming Xu, Zhendong Chen, Lijie Song, Xing Zhang, Ying Cheng, Yanqiao Zhang, Feng Ye, Zhiping Li, Fei Yin, Dongmei Ji, Heli Gao, Yi Li, Wei Chen, Minjie Yang, Desheng Weng, Chunjiao […]


HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy —   Hong Kong, Shanghai & Florham Park, NJ — Thursday, […]